Shield Therapeutics(DE:1JS)
€0.03+0.00 (+0.00%)
DE:1JS
Shield Therapeutics financials statements
€0.03
At close:+0.00 (+0.00%)
Shield Therapeutics (1JS) Income Statement
2 Followers
Shield Therapeutics Income Statement
Last quarter (Q2 2026), Shield Therapeutics's total revenue was £30.12M, an increase of 148.11% from the same quarter last year. In Q2, Shield Therapeutics's net income was £-2.23M. See Shield Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Mar 26 | Dec 24 | Dec 23 | Dec 22 | Jun 22 |
|---|---|---|---|---|---|
| £ 50.74M | £ 32.18M | £ 16.54M | £ 4.48M | £ 1.52M | |
| £ 22.38M | £ 13.22M | £ 5.09M | £ 2.00M | £ -1.67M | |
| £ 32.68M | £ 37.80M | £ 44.69M | £ 52.21M | £ 18.74M | |
| Depreciation and Amortization | £ 1.14M | £ 1.43M | £ 1.35M | £ 2.33M | £ 2.21M |
| £ -9.16M | £ -21.26M | £ -38.28M | £ -46.61M | £ -17.69M | |
| £ -10.30M | £ -22.87M | £ -31.33M | £ -26.39M | £ -20.41M | |
| £ -7.20M | £ -3.68M | £ -1.04M | £ -13.67M | £ 498.00K | |
| £ -17.50M | £ -26.56M | £ -32.38M | £ -40.08M | £ -19.91M | |
| £ -18.03M | £ -26.61M | £ -33.29M | £ -40.44M | £ -19.34M | |
| Per Share Metrics | |||||
| Basic EPS | £ -0.02 | £ -0.03 | £ -0.05 | £ -0.17 | £ -0.09 |
| Diluted EPS | £ -0.02 | £ -0.03 | £ -0.05 | £ -0.17 | £ -0.09 |
| Weighted Average Shares Outstanding | 881.34M | 905.20M | 722.54M | 233.19M | 204.41M |
| Weighted Average Shares Outstanding (Diluted) | 881.34M | 905.20M | 722.54M | 233.19M | 204.41M |
Currency in GBP
